معرفی
Dr. David Fiellin is a Professor of Medicine (General Medicine), Emergency Medicine, and Public Health at Yale School of Medicine. He serves as Vice Chief of Faculty Affairs in General Internal Medicine and Director of the Yale Program in Addiction Medicine. His work bridges primary care, emergency medicine, and addiction treatment, focusing on opioid and alcohol use disorders in diverse clinical settings. Fiellin holds NIH-funded research grants and has led implementation science initiatives to expand access to evidence-based addiction treatments.
Education: MD from Emory University (1991), residency and chief residency at Yale-New Haven Hospital, and postdoctoral training at Yale School of Medicine.
Research Interests: Fiellin investigates integrating addiction treatments into primary care, emergency departments, and HIV clinics. Key areas include buprenorphine prescribing in emergency settings, contingency management for alcohol use, and pharmacotherapy innovations like GLP-1 agonists for alcohol reduction.
Recent Work: Recent publications address cost-effectiveness of buprenorphine implementation, opioid withdrawal management in EDs, and HIV-patient alcohol treatment. His 2025 studies explore GLP-1 agonists' impact and stepped care interventions.
Awards: Recognized with the James H. Tharp Award (2022), Dan Anderson Research Award (2016), and multiple leadership roles in addiction medicine organizations.
Grants/Advising: Principal investigator on NIH grants, mentors trainees, and collaborates with teams like the Veterans Aging Cohort Study. Leads initiatives at the Center for Implementation Science and Wu Tsai Institute.
Labs/Teams: Active in the Center for Brain & Mind Health, Yale Center for Implementation Science, and Substance Abuse Research programs. Collaborates with interdisciplinary groups on pharmacotherapy and policy interventions.